If you are still having problems viewing this message, please click here for additional help.

Nature Reviews Urology

July 2017 Volume 14 Number 7Advertisement
Nature Reviews Urology cover
2015 2-year Impact Factor 5.957 Journal Metrics 2-year Median 4
In this issue
Research Highlights
News and Views

Also this month
 Featured article:
Incontinence: The dilemma with comparing efficacy of OAB treatments
Arun Sahai and Sachin Malde
Call for nominations: 2017 John Maddox Prize for Standing up for Science.

Recognising the work of individuals who promote science in the face of hostility. Winners will be announced at a reception in London, as well as in Nature, and will receive £2,000. Closing date for nominations is 31st July 2017.
Click to learn more
Recommend to library

Prostate cancer: Twist and Skp2 castration resistance
Published online: 11 April 2017
p387 | doi:10.1038/nrurol.2017.56


Prostate cancer: Antagonizing AR: MYC affects transcription
Published online: 25 April 2017
p388 | doi:10.1038/nrurol.2017.62


Prostate cancer: Transdifferentiation results in resistance
Published online: 03 May 2017
p388 | doi:10.1038/nrurol.2017.68


Prostate cancer: Targeting the core of resistance
Published online: 20 April 2017
p389 | doi:10.1038/nrurol.2017.61


Kidney cancer: Tracking and therapy selection using ctDNA
Published online: 03 May 2017
p389 | doi:10.1038/nrurol.2017.66


Prostate cancer: PCA3 as a Grade Reclassification Predictor
Published online: 09 May 2017
p390 | doi:10.1038/nrurol.2017.70


Prostate cancer: Circulating free DNA as biomarker
Published online: 16 May 2017
p390 | doi:10.1038/nrurol.2017.74


Surgery: Retzius-sparing RARP improves continence recovery
Published online: 23 May 2017
p390 | doi:10.1038/nrurol.2017.79


Prostate cancer: New AR co-regulator with dichotomous functions
Published online: 23 May 2017
p391 | doi:10.1038/nrurol.2017.78



Prostate cancer: AZGP1 expression predicts favourable outcomes | Kidney cancer: Bap1 and Pbrm1 determine tumour grade | Infection: Intravesical gentamicin ameliorates recurrent UTI | Pain: Chondroitin sulfate is superior to hyaluronic acid

Nature Reviews Urology
JOBS of the week
Postdoctoral Fellows and Research Scientist
Boston Children´┐Żs Hospital and Harvard Medical School
More Science jobs from
Nature Reviews Urology
International Colloquium on Medical, Pharma & Drug Studies
Brisbane, Australia
More science events from
Incontinence: The dilemma with comparing efficacy of OAB treatments
Arun Sahai & Sachin Malde
Published online: 16 May 2017
p393 | doi:10.1038/nrurol.2017.67
The comparative efficacy of drugs for the management of overactive bladder syndrome (OAB) remains undefined. A new indirect treatment comparison demonstrates similar efficacy of mirabegron versus several antimuscarinic drugs and onabotulinum toxin A in a number of outcome measures. Head-to-head trials of these agents are still required to optimize the management of patients with OAB.
Full Text | PDF
Sepsis: Prophylactic antibiotic for prostate biopsy: the carbapenem gamble
Deepak K. Pruthi & Michael A. Liss
Published online: 23 May 2017
p394 | doi:10.1038/nrurol.2017.73
Sepsis is an infrequent but serious adverse risk of transrectal ultrasonography-guided prostate biopsy. A new study evaluated whether the use of single-dose ertapenem, a broad-spectrum antibiotic, resulted in increased carbapenem resistance following biopsy. However, physicians need to carefully consider the risks of antibiotic resistance when balancing the benefit of broad-spectrum antibiosis against a 1% risk of sepsis.
Full Text | PDF
Prostate cancer: Comparing quality of life outcomes after prostate cancer treatment
Thenappan Chandrasekar & Derya Tilki
Published online: 13 June 2017
p396 | doi:10.1038/nrurol.2017.81
Life expectancy after primary treatment for localized prostate cancer is long, so the importance of functional outcomes and quality-of-life measures cannot be underestimated. Careful assessment of the data, with an emphasis on patient selection, definition of clinical significance, and length of follow-up duration, is essential.
Full Text | PDF
Prostate cancer: 'The prostate' in patients with metastatic prostate cancer: to treat or not to treat?
Fred Saad
Published online: 16 May 2017
p398 | doi:10.1038/nrurol.2017.72
Advances in understanding of prostate cancer biology and improved treatment options have changed management of metastatic prostate cancer. Escape of the malignancy from the prostatic capsule no longer means that treatment is focused on limiting systemic spread, and data suggest that local treatment of the prostate is beneficial, even in men whose tumour has spread.
Full Text | PDF
Nature Awards for Mentoring in Science — Spain

Your mentor could win €10,000

Nominations are now open
The potential of organoids in urological cancer research
Shangqian Wang, Dong Gao & Yu Chen
Published online: 23 May 2017
p401 | doi:10.1038/nrurol.2017.65
3D organoids are valuable tools for increasing understanding of disease biology. In this Review, the authors describe how successful application of organoids into urological cancer research can further our understanding of these diseases and provide preclinical cancer models to aid precision medicine.
Abstract | Full Text | PDF
The evolution of brachytherapy for prostate cancer
Nicholas G. Zaorsky et al.
Published online: 30 June 2017
p415 | doi:10.1038/nrurol.2017.76
Brachytherapy offers an excellent treatment option for definitive and salvage treatment of prostate cancer, with excellent oncological outcomes, limited toxic effects, and good quality of life for patients. However, use of prostate brachytherapy has been declining. In this comprehensive Review, Zaorsky and colleagues consider the evolution of brachytherapy from its inception to contemporary practice, from historical background to current indications and contraindications, underlying radiophysics and technical aspects, cost, and clinical outcomes.
Abstract | Full Text | PDF
Incontinence in the elderly, 'normal' ageing, or unaddressed pathology?
William Gibson & Adrian Wagg
Published online: 11 April 2017
p440 | doi:10.1038/nrurol.2017.53
The risk of urinary incontinence and other lower urinary tract (LUT) symptoms increases substantially with advancing age; however, such symptoms can emerge in otherwise healthy individuals. In this Review, the authors describe the changes in LUT physiology that take place during the ageing process, and whether or not these changes arise as a consequence of 'normal', healthy ageing, or unaddressed pathology.
Abstract | Full Text | PDF
nature events
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.

Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com
More Nature Events
*Journal Citation Reports, Thomson, 2008. Nature Reviews Urology was previously published as Nature Clinical Practice Urology.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount
(You will need to log in to be recognised as a nature.com registrant).

For further technical assistance, please contact our registration department

For print subscription enquiries, please contact our subscription department

For other enquiries, please contact our feedback department

Springer Nature | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA

Springer Nature's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston

Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW.

© 2017 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved.

Springer Nature